Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Eur J Clin Microbiol Infect Dis ; 43(5): 895-904, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38472522

RESUMO

PURPOSE: Campylobacter is a frequent cause of enteric infections with common antimicrobial resistance issues. The most recent reports of campylobacteriosis in Italy include data from 2013 to 2016. We aimed to provide national epidemiological and microbiological data on human Campylobacter infections in Italy during the period 2017-2021. METHODS: Data was collected from 19 Hospitals in 13 Italian Regions. Bacterial identification was performed by mass spectrometry. Antibiograms were determined with Etest or Kirby-Bauer (EUCAST criteria). RESULTS: In total, 5419 isolations of Campylobacter spp. were performed. The most common species were C. jejuni (n = 4535, 83.7%), followed by C. coli (n = 732, 13.5%) and C. fetus (n = 34, 0.6%). The mean age of patients was 34.61 years and 57.1% were males. Outpatients accounted for 54% of the cases detected. Campylobacter were isolated from faeces in 97.3% of cases and in 2.7% from blood. C. fetus was mostly isolated from blood (88.2% of cases). We tested for antimicrobial susceptibility 4627 isolates (85.4%). Resistance to ciprofloxacin and tetracyclines was 75.5% and 54.8%, respectively; resistance to erythromycin was 4.8%; clarithromycin 2% and azithromycin 2%. 50% of C. jejuni and C. coli were resistant to ≥ 2 antibiotics. Over the study period, resistance to ciprofloxacin and tetracyclines significantly decreased (p < 0.005), while resistance to macrolides remained stable. CONCLUSION: Campylobacter resistance to fluoroquinolones and tetracyclines in Italy is decreasing but is still high, while macrolides retain good activity.


Assuntos
Antibacterianos , Infecções por Campylobacter , Campylobacter , Testes de Sensibilidade Microbiana , Humanos , Infecções por Campylobacter/epidemiologia , Infecções por Campylobacter/microbiologia , Itália/epidemiologia , Feminino , Masculino , Adulto , Antibacterianos/farmacologia , Pessoa de Meia-Idade , Adulto Jovem , Adolescente , Idoso , Campylobacter/efeitos dos fármacos , Campylobacter/isolamento & purificação , Criança , Pré-Escolar , Lactente , Fezes/microbiologia , Farmacorresistência Bacteriana , Idoso de 80 Anos ou mais , Recém-Nascido , Campylobacter jejuni/efeitos dos fármacos , Campylobacter jejuni/isolamento & purificação
2.
Microb Drug Resist ; 30(2): 91-100, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38150043

RESUMO

Multidrug-resistant Escherichia coli, particularly carbapenemase producers, are a major source of concern. This study aims to investigate the long-term epidemiology of Verona integron-encoded metallo-ß-lactamase (VIM)-producing E. coli in the health district of Bolzano, Northern Italy, by examining the phenotypic and genotypic characteristics of 26 isolates obtained during 2005-2020. Isolates were identified with matrix-assisted laser desorption/ionization time-of-flight, susceptibility testing was by Vitek 2, Sensititre, and Etest; carbapenemase activity was confirmed by Etest and Carbapenemase Inactivation Method (CIM) test; and the VIM-antigen was identified by the NG-Test CARBA 5. Genome sequencing was performed on an Illumina MiSeq platform. Carbapenem minimum inhibitory concentrations varied across methodologies, and overall category agreement between phenotypic methods was low. All 23 sequenced isolates contained blaVIM-1. Eleven (47.8%) isolates belonged to the clonal lineage ST131, with fimH30 being the most common subclone. In Bolzano ST131-fimH30 was present as early as 2005. While the ST131 clonal lineage predominated for the first 10 years, various clonal lineages were present, especially in subsequent years, indicating the concurrent circulation of multiple clonal lineages. Future efforts should focus on the implementation of surveillance methods, including genomic analysis, as well as the use of updated infection control strategies and antibiotic stewardship programs to prevent the spread of these carbapenem-resistant strains.


Assuntos
Enterobacteriáceas Resistentes a Carbapenêmicos , Escherichia coli , Antibacterianos/farmacologia , Integrons/genética , Testes de Sensibilidade Microbiana , Proteínas de Bactérias/genética , beta-Lactamases/genética , beta-Lactamases/metabolismo , Carbapenêmicos/farmacologia , Enterobacteriáceas Resistentes a Carbapenêmicos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA